Rethinking cardiovascular therapy - The effect of irbesartan on circulating microparticles and endothelial progenitor cells in patients with hypertension and dyslipidemia

Farmacia

Volumn 62, Issue 1, 2013, Pages 93-106

  Bǎdila, Elisabeta ^a,b   Daraban, Ana Maria ^a   Ghiorghe, Silviu ^a   Georgescu, Adriana ^c   Alexandru, Nicoleta ^c   Bartoş, Daniela ^a,b   Tîrziu, Cristina ^a  

^a Clinical Emergency Hospital   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Circulating microparticles; Endothelial dysfunction; Endothelial progenitor cells; Irbesartan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CADHERIN; CD133 ANTIGEN; CD34 ANTIGEN; CREATININE; DIURETIC AGENT; HOMOCYSTEINE; IRBESARTAN; URIC ACID; VASCULOTROPIN RECEPTOR;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERTENSION; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; MONONUCLEAR CELL; VASODILATATION;

EID: 84893696783     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol. 2005;16:3381-3388
2. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:1268-1275
3. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells. A new putative therapeutic effect of Angiotensin II receptor antagonists. Hypertension. 2005; 45: 526-529.
4. Drǎgoi CM, Mitrea N, Arsene AL, Ilie M, Nicolae AC, Jurkat E 6.1 cell line studies regarding the effects of some bio-indols on the membrane fluidity, Farmacia, 2012, 60(1), 13-20
5. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104: 2649-2652.
6. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by Angiotensin II is mediated via Ang II Receptor Type I/NADPH Oxidase/Rho Kinase Pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol. 2011;31:1898-1907
7. Chironi, GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet J-M, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009; 335:143-151.
8. Cooke JP. The endothelium: a new target for therapy. Vascular Medicine, 2000; 5: 49-53
9. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol.1986; 57: 450-458.
10. Georgescu A, Alexandru N, Popov D, Amuzescu M, Andrei E, Zamfir C, Maniu H, Badila A. Chronic venous insufficiency is associated with elevated level of circulating microparticles. J Thrombosis Haemostasis. 2009; 7 (9): 1566-1575.
11. Georgescu, A., N. Alexandru, E. Andrei, I. Titorencu, E. Dragan, C. Tarziu, S. Ghiorghe, E. Badila, D. Bartos, D. Popov 2012. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. Journal of Thrombosis and Haemostasis 10: 680-691.
12. Georgescu A. Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy. World J Diabetes 2011 June 15; 2(6): 92-97.
13. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 Aug;106(6):653-8.
14. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH: Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatric Diabetes 2007, 8:193-198
15. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346.
16. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. Journal of the American College of Cardiology.2005; 45: 1458-1460.
17. Hill JM, Zalos G, Halcor JPJ, Schenke BA, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
18. Hristov M and Weber C. Progenitor cell trafficking in the vascular wall. Journal of Thrombosis and Haemostasis. 2009;7 (Suppl. 1): 31-34
19. Lekakis J, Abraham P, Balbarini A et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. European Journal of Cardiovascular Prevention & Rehabilitation. 18(6) 775-789
20. Leroyer AS, Tedqui A, Boulanger CM. Role of microparticles in atherothrombosis. J Intern Med. 2008 May;263(5):528-37
21. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
22. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101:841-843.
23. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag. 2008 February; 4(1): 89-101
24. Bǎcanu EV, Lixandru D, Stoian I, Vîrgolici B, Mohora M, Arsene AL, Ionescu-Tîrgovişte C, Correlations between obesity antropometric markers, adipocytokines and monocytes oxidative stress status in type 2 diabetic patients, Farmacia, 2012, 60(2), 194-205
25. Silvestre JS, Levi BI. Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzime inhibitors. European Heart Journal Supplements (2009) 11 (Supplement E), E17-E21
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. European Heart Journal (2007) 28, 1462-1536
27. Woywodt A, Bahlmann FH, De Groot K, Haller H, Haubitz M. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant. 2002;17:1728-1730
28. Xu Q. Progenitor cells in vascular repair. Curr Opin Lipidol. 2007;18:534-539.